In Brief: Summit Technology v. Chiron Technolas GmbH
This article was originally published in The Gray Sheet
Summit Technology v. Chiron Technolas GmbH: Chiron Technolas appeals German court ruling that the firm's Keracor 116 and Schwind GmbH's Keratom ophthalmic excimer laser systems infringe a Summit patent ("The Gray Sheet" Sept. 4, p. 14). Chiron Technolas is prohibited from manufacturing, selling or using the laser systems in Germany following the posting of a bond by Summit that was necessary for enforcement of an injunction issued by the German court. In addition to the appeal, Chiron Technolas has also filed a nullity action with the German patent office, Summit states. Schwind also plans to file an appeal. Coherent, which distributes the Schwind laser, states that no interruptions in product availability are anticipated since its laser can be offered with a newly developed optical delivery system that does not infringe "whenever it becomes necessary to do so," Coherent states...
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.